Added today: A Phase 1b, Prospective, Randomized, Double-Blind, Placebo- Controlled, Single-Dose, Multicenter, Safety Study of FX-322 Administered by Intratympanic Injection in Adults With Severe Sensorineural Hearing Loss.
This is a Phase 1b placebo-controlled, double-blind, single-dose safety study of intratympanic FX-322 dosed in subjects with severe sensorineural hearing loss.
Approximately 30 subjects are planned to be enrolled in this study. The subjects will be randomized to receive one dose FX-322 (24) or placebo (6) and will return for safety, otologic, and audiologic assessments at Days 30 and 90 after the study injection.
What makes this new FX-322 trial different (compared to the trial that was added last month)?
This new study is for severe sensorineural hearing loss (previously added study is for age-related hearing loss). The inclusion criteria requires a “pure tone average of “26-70 dB at 500Hz, 1000Hz, 2000Hz, and 4000Hz at screening in the ear to be injected.”
Does it include a Tinnitus Assessment as a secondary outcome measure?
Yes.
Measured by the Tinnitus Functional Index (TFI), with a scale ranging from 0 to 100 that defines severity categories based on 25 self-reported answers.
What else? More fun facts:
Study is Recruiting and will enroll 30 participants. It does involve a placebo group however the ratio is 4:1 which means most (24) of the participants will get FX-322.
If you like those odds, here are the states where clinical trial sites are located:
- Florida
- Nebraska
- New York
- Texas
- Virginia
Could more locations be added?
Very possible. We will post an update if/when more sites are added.
Here is the official link to the study:
https://clinicaltrials.gov/ct2/show/NCT04629664
More FX-322 updates:
If you want ALL of the FX-322 updates and exclusive hearing loss treatment-updates sign up for the free email newsletter.